CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
ORMD-0801 (qd) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02954601
NCT02954601Phase 2Completed

A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Compare Safety, Efficacy, and Pharmacodynamics of Single and Multiple Doses of ORMD-0801 in Adult Subjects With Type 2 Diabetes Mellitus

Oramed, Ltd.·interventional·Posted Nov 3, 2016·Updated Jul 12, 2018

In Brief

A Phase 2 clinical trial evaluating ORMD-0801 (qd), ORMD-0801 (bid), and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive. Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsIntegrium

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 3, 2016
Enrollment StartOct 1, 2016
Primary CompletionFeb 24, 2017
Study CompletionMar 15, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.7 years ago

Interventions

ORMD-0801 (qd)drug

Dose 1 = ORMD-0801 (qd)

ORMD-0801 (bid)drug

Dose 2 = ORMD-0801 (bid)

ORMD-0801 (tid)drug

Dose 3 = ORMD-0801 (tid)

Placeboother

fish oil placebo